Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)



Status:Recruiting
Conditions:High Cholesterol
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:9/9/2018
Start Date:October 10, 2017
End Date:June 17, 2019
Contact:Clinical Trials Administrator
Email:clinicaltrials@regeneron.com
Phone:844-734-6643

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Homozygous Familial Hypercholesterolemia

The primary objective of the study is to demonstrate the reduction of low-density lipoprotein
cholesterol (LDL-C) with alirocumab subcutaneous (SC) every 2 weeks (Q2W) in comparison to
placebo after 12 weeks of treatment.


Note: The information listed below is not intended to contain all considerations relevant
to a patient's potential participation in this clinical trial, therefore not all
inclusion/exclusion criteria are listed.

Key Inclusion Criteria

1. Diagnosis of HoFH by at least 1 of the following genotype or clinical criteria (all
patients on LDL apheresis must be diagnosed based on genotype):

1. Documented homozygous or compound heterozygous mutations in both low-density
lipoprotein receptor (LDLR) alleles

2. Presence of homozygous or compound heterozygous mutations in Apo B or PCSK9

3. Presence of double heterozygous mutations, i.e, mutations on different genes in
the LDLR, Apo B or PCSK9 alleles

4. Untreated TC >500 mg/dL (12.93 mmol/L) and TG <300 mg/dL (3.39 mmol/L) AND Both
parents with history of TC >250 mg/dL (6.46 mmol/L) OR cutaneous or tendinous
xanthoma before age 10

2. Receiving a stable dose of a statin at the screening visit (documentation if statin
ineffective or patient unable to tolerate statin)

Key Exclusion Criteria:

1. Documented evidence of a null mutation in both LDLR alleles

2. Use of a PCSK9 inhibitor within 10 weeks from screening visit

3. Background medical lipid modifying therapy (LMT) that has not been stable for at least
4 weeks (6 weeks for fibrates, 24 weeks for mipomersen, 12 weeks for maximum tolerated
dose of lomitapide) before the screening visit.

4. LDL apheresis schedule/apheresis settings that have not been stable for at least 8
weeks before the screening visit or an apheresis schedule/settings that is not
anticipated to be stable over the next 24 weeks.

5. Use of nutraceuticals or over-the-counter (OTC) therapies known to affect lipids, at a
dose/amount that has not been stable for at least 4 weeks prior to the screening visit
or between the screening and randomization visits.

6. Chronic use of systemic corticosteroids, unless on a stable regimen of 10 mg daily
prednisone equivalent or less for at least 6 weeks prior to randomization. Note:
topical, intra-articular, nasal, inhaled and ophthalmic steroid therapies are not
considered as 'systemic' and are allowed

7. Systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg at the
screening visit (1 repeat measurement is allowed).

8. History of a myocardial infarction (MI), unstable angina leading to hospitalization,
coronary artery bypass graft surgery, percutaneous coronary intervention ,
uncontrolled cardiac arrhythmia, carotid surgery or stenting, stroke, transient
ischemic attack, valve replacement surgery, carotid revascularization, endovascular
procedure or surgical intervention for peripheral vascular disease within 3 months
prior to the screening visit.
We found this trial at
5
sites
?
mi
from
Portland, OR
Click here to add this to my saved trials
Boca Raton, Florida 33434
?
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Cincinnati, Ohio
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Innsbruck,
Click here to add this to my saved trials
New York, New York
?
mi
from
New York, NY
Click here to add this to my saved trials